Clinical efficacies of different neoadjuvant therapies for non-small cell lung cancer

Highlights • Comparison of major neoadjuvant therapies for locally advanced NSCLC.• Real world cases from one institution using the same evaluation criteria.• Disparity between short-term efficacy of radiology and pathology.• The impact of MPR on long-term survival for different neoadjuvant therapies.• Positive lymph nodes increased the risk of postoperative recurrence.

• Publication year

  2024

• Venue

  Translational Oncology

• Publication date

  2024-11-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.tranon.2024.102195PMID 39550889PMCID 11615615
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Perioperative Nivolumab in Resectable Lung Cancer.

  2024cited by this paper
• Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.

  2024cited by this paper
• Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma based on real-world cumulative clinical data

  2024cited by this paper
• Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.

  2023cited by this paper
• International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.

  2023cited by this paper
• Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives

  2023cited by this paper
• Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

  2023cited by this paper
• Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.

  2023cited by this paper
• Targeted therapy for lung cancer: Beyond EGFR and ALK

  2023cited by this paper
• Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

  2023cited by this paper
• Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis

  2023cited by this paper
• Checkpoint Inhibitors Up Survival in Early-Stage Lung Cancer.

  2023cited by this paper
• Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients

  2022cited by this paper
• Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.

  2022cited by this paper
• Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.

  2022cited by this paper
• Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.

  2022cited by this paper
• Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

  2022cited by this paper
• Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

  2022cited by this paper
• Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

  2022cited by this paper
• Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials

  2022cited by this paper
• Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis

  2022cited by this paper
• Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review.

  2022cited by this paper
• Revisiting neoadjuvant therapy in non-small-cell lung cancer.

  2021cited by this paper
• Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy.

  2021cited by this paper
• Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.

  2021cited by this paper
• Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer

  2021cited by this paper
• Toward personalized treatment approaches for non-small-cell lung cancer

  2021cited by this paper
• Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer

  2021cited by this paper
• IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

  2020cited by this paper
• The Effect of Advances in Lung-Cancer Treatment on Population Mortality.

  2020cited by this paper
• Emerging therapeutic agents for advanced non-small cell lung cancer

  2020cited by this paper
• Trends and advances in tumor immunology and lung cancer immunotherapy

  2016cited by this paper
• A comprehensive map of molecular drug targets

  2016cited by this paper
• Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

  2014cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

  2007cited by this paper
• A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

  1994cited by this paper

• NeoPred: dual-phase CT AI forecasts pathologic response to neoadjuvant chemo-immunotherapy in NSCLC

  2025cites this paper